This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Atherosclerosisa key driver of cardiovascular disease (CVD)continues to be a significant global health issue. While advances in treatment have reduced mortality in some regions, the atherosclerosis prevention remains challenging. Explore the growing burden of CVD, the rise of new risk factors, and barriers to prevention: The Rising Global Burden of Cardiovascular Disease CVD is now the leading cause of death worldwide, with low- and middle-income countries (LMICs) experiencing the highest burd
Smoking is a well-known health hazard, contributing to a wide array of diseases and conditions. Its effects on the heart are particularly alarming, as smoking significantly increases the risk of cardiovascular diseases (CVDs) and complicates medical procedures such as minimally invasive or bloodless heart surgeries. Understanding how smoking affects the heart and raises surgery risks can empower individuals to make healthier choices and improve outcomes when surgical intervention is necessary.
Bayers FINEARTS-HF study revealed that finerenone could be poised to become the next big heart failure treatment at ESC 2024, and a new series of JACC sub-studies just further strengthened its case. FINEARTS-HF explored the effects of finerenone in ~6k HFmrEF/HFpEF patients and found that the drug significantly reduced worsening HF events and CV death versus placebo.
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Large and rare duplications and deletions in a chromosome region known as 22q11.2 , which involves genes that regulate cardiac development, are linked to nonsyndromic bicuspid aortic valve disease.
This study pointed to the abilities of patients with acne to adapt to stress and adversity as helpful in making skin-related quality of life improvements.
Among patients with asymptomatic severe aortic stenosis, early TAVR was superior to clinical surveillance in reducing the incidence of death, stroke, or unplanned hospitalization for cardiovascular causes.
Among patients with asymptomatic severe aortic stenosis, early TAVR was superior to clinical surveillance in reducing the incidence of death, stroke, or unplanned hospitalization for cardiovascular causes.
The approval is based on data from the phase 3 VIVID-1 study and marks mirikizumabs second approval in IBD, the first being ulcerative colitis in 2023.
Research has established a clear link between racial and ethnic disparities in maternal heart health and higher risks of preterm birth, preeclampsia and cardiovascular issues for Black and Hispanic mothers and their babies.
A new study showed ADHD incidence trends fluctuated between 2016-2023, with adult diagnoses rising post-COVID-19 and adolescent rates remaining stable after an initial decline.
A team from Charleston, S.C.-based MUSC Health's Heart and Vascular Center became the first in the country to implant the Topaz device, a new transcatheter tricuspid heart valve replacement system.
Panelists walk through a patient case scenario involving Maria, a 29-year-old woman diagnosed with familial chylomicronemia syndrome (FCS), offering recommendations from each of their specialty perspectives, including dietary modifications, triglyceride-lowering medications, and patient education on managing the condition to prevent recurrent pancreatitis and improve overall quality of life.
Circulation, Ahead of Print. The use of assisted reproductive technology (ART) is growing, both to assist individuals with infertility and for fertility preservation. Individuals with cardiovascular disease (CVD), or risk factors for CVD, are increasingly using ART. Thus, knowing how to care for patients undergoing ART is important for the cardiovascular clinician.
The January 15, 2025 SOCS News Update highlights research ongoing/upcoming initiatives and awards, the My Best Winter Skin Campaign, and the TORPEDO program.
In this interview, Drs. Alison Bailey and Milton Packer examine the power of tirzepatide expanding beyond weight loss and treating diabetes in addition to reducing heart failure events in patients with obesity-related HFpEF.
The Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) trial enrolled patients with vascular disease, but excluded patients requiring oral anticoagulation.
The analysis of UnitedHealth Group claims data found the per-patient cost of cirrhosis care exceeded that of HF and COPD by 21.7% and 55.0%, respectively.
Implantable cardiac monitors (ICMs) provide valuable insights into managing atrial fibrillation (AF). Data suggest that ICMs increase AF detection, but their impact on management is still uncertain.
With a Phase 3 trial expected in 2025, linsitinib is the first oral small-molecule therapy to demonstrate statistical significance in thyroid eye disease.
Cardioneuroablation (CNA) targets ganglionated plexus (GP) to treat neurally-mediated syncope, yet a standardized GP identification method is lacking. Post-processing of cardiac computed tomography (CT) identifies epicardial fat thus allowing for fat pad identification. While CT-guided CNA's feasibility is documented, data about GP anatomy and comprehensive evaluations of GP targeting methods remain scarce.
2 phase 3 trials show iptacopan improves fatigue, quality of life, and hematologic markers in C5i-experienced or -naive patients with paroxysmal nocturnal hemoglobinuria.
Atypical atrial tachycardia (AT) is a commonly encountered rhythm disorder especially in patients with underlying atrial scar. Peak frequency (PF) annotation of bipolar electrograms is a novel method, which mainly aims to discriminate near-field and far-field signals.
Anti-CGRP monoclonal antibodies for migraine prevention were not linked to increased cardiovascular risk, per a Medicare study, addressing earlier safety concerns.
Abstract Aims It is unclear whether there is a causal relationship between social determinants of health (SDoH) and mortality in patients with chronic heart failure (CHF). In this study, we assessed causality using inverse probability weighting (IPW) of marginal structural models (MSMs) during the course of CHF. Methods and results A total of 1377 patients with CHF were enrolled in this multi-centre, prospective cohort study from September 2017 onwards.
Panelists discuss how the SPORT trial demonstrated the limited efficacy of dietary supplements compared with traditional lipid-lowering therapies in reducing LDL-C levels.
Aortic-valve stenosis is an increasingly common clinical condition in the aging population. Population studies indicate a prevalence of up to 2.5% even among persons younger than 75 years of age, with a prevalence of up to 8% in those 75 years of age or older, with large geographic differences between.
Panelists discuss how newer nonstatin therapies, such as PCSK9 inhibitors (inclisiran, alirocumab, evolocumab) and bempedoic acid, offer additional options for LDL-C reduction and cardiovascular risk management.
This was submitted by Hans Helseth, who is applying to med school and who is working as an EKG tech right now. Smith : This patient presented years ago, but came in again while Hans was working. He looked back in time in the patient's chart and saw these ECGs and immediately recognized that they manifested subtle OMI. Also : See Ken Grauer's excellent comments at the bottom.
Background Post-pneumonectomy bronchopleural fistula (BPF) is a life-threatening event whose treatment is not standardized. Case presentation We report the management of a 28-year-old patient with a 3-year history of BPF complicating right pneumonectomy for congenital emphysema. Despite closure by an Amplatzer device, the patient had chronic pyothorax and severely deteriorated general health and quality of life.
BackgroundDextrocardia is a rare congenital condition, affecting approximately 1 in 10,00012,000 individuals. When combined with atrial fibrillation (AF), it becomes even rarer. One-stop surgery, including combined radiofrequency ablation (RFA) and left atrial appendage occlusion (LAAO), has become a common clinical treatment for patients with AF who develop cerebral infarction despite regular oral anticoagulants.
In this episode, I sit down with Brian Heiderscheit , a professor in the Department of Orthopedics and Rehabilitation at the University of Wisconsin-Madison and director of the Badger Athletic Performance program. Brian also collaborates with Springbok Analytics, a company specializing in advanced full-body MRI scans. Together, we discuss my recent experience with a Springbok scan, how MRI data is revolutionizing athlete performance analysis, and actionable insights for reducing injury risks and
IntroductionHypertrophic cardiomyopathy (HCM) is a common genetic heart disorder. It is characterized by left ventricular hypertrophy and impaired cardiac function, with forms categorized into obstructive (oHCM) and nonobstructive (nHCM). Traditional treatments address symptoms but not the underlying disease mechanism, highlighting the need for novel therapies.
ObjectiveThis meta-analysis elucidates the efficacy of the Transradial Band Device (TR Band) in minimizing complications like radial artery occlusion and hematoma, preserving heart health, and enhancing blood flow post-transradial catheterization.MethodsA comprehensive literature search across databases including PubMed, Cochrane, and Embase examined the impact of radial artery compression techniques and decompression times on complications.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
59 
Let's personalize your content